drugset

drugset / Trial / NCT00747175

A Study to Evaluate Safety, Tolerability and P-Glucose After Multiple Ascending Oral Doses of AZD1656 in Type 2 Diabetes

NCT00747175 ↗

Phase 1 Completed 52 enrolled AstraZeneca

RandomizedFactorialSingle-blindTreatment

Summary

The purpose of this study is to assess safety and tolerability of AZD1656 after multiple repeated oral doses in patients with type 2 diabetes

Timeline

Start: 2008-08
Primary completion: 2009-04
Completion: 2009-04

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	AZD1656	Small molecule	—	Oral

Indications